[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522384":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":201,"collaborators":11,"id":203,"slug":204,"hasResults":205,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":11,"eligibilityCriteria":209,"healthyVolunteers":205,"sex":210,"minAge":211,"maxAge":11,"enrollmentInfo":212,"targetDuration":11,"studyType":215,"phases":216,"briefSummary":218,"conditions":219,"keywords":11,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":230},{"fullName":5,"class":6},"Innovent Biologics (Suzhou) Co. Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"IBI363","EXPERIMENTAL",null,[13],"Biological: IBI363",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"BIOLOGICAL","IBI363 monotherapy",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Haiyun Zuo","CONTACT","0512-69566088","haiyun.zuo@innoventbio.com",[26,45,52,67,82,100,115,130,145,156,171,186],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Beijing Cancer Hospital","RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":35,"coordinates":36},"Point",[37,38],116.39723,39.9075,{"lat":38,"lon":37},[41],{"name":42,"role":22,"phone":43,"phoneExt":11,"email":44},"Jun Guo","13911233048","guoj307@126.com",{"facility":46,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":47,"geoPoint":49,"contacts":50},"Peking University Cancer Hospital & Institute, Beijing, China,",{"type":35,"coordinates":48},[37,38],{"lat":38,"lon":37},[51],{"name":42,"role":22,"phone":43,"phoneExt":11,"email":44},{"facility":53,"status":28,"city":54,"state":55,"zip":56,"country":32,"countryCode":33,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Fujian Cancer Hospital","Fuzhou","Fujian","350000",{"type":35,"coordinates":58},[59,60],119.30611,26.06139,{"lat":60,"lon":59},[63],{"name":64,"role":22,"phone":65,"phoneExt":11,"email":66},"Yu Chen","18950395132","chenyu1980@fjmu.edu.cn",{"facility":68,"status":28,"city":69,"state":70,"zip":71,"country":32,"countryCode":33,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"The Third people's hospital of Zhengzhou","Zhengzhou","Henan","450044",{"type":35,"coordinates":73},[74,75],113.64861,34.75778,{"lat":75,"lon":74},[78],{"name":79,"role":22,"phone":80,"phoneExt":11,"email":81},"Xianbin Liang","15038212930","Wslxb666@126.com",{"facility":83,"status":28,"city":84,"state":85,"zip":86,"country":32,"countryCode":33,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Hunan Cancer Hospital","Changsha","Hunan","410031",{"type":35,"coordinates":88},[89,90],112.97087,28.19874,{"lat":90,"lon":89},[93,97],{"name":94,"role":22,"phone":95,"phoneExt":11,"email":96},"Xianan Li","18874933879","lixianan2001@163.com;puxingxiang@hnca.org.cn",{"name":98,"role":22,"phone":99,"phoneExt":11,"email":11},"Xingxiang Pu","15874180022",{"facility":101,"status":28,"city":102,"state":103,"zip":104,"country":32,"countryCode":33,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Nanjing Drum Tower Hospital","Nanjing","Jiangsu","210000",{"type":35,"coordinates":106},[107,108],118.77778,32.06167,{"lat":108,"lon":107},[111],{"name":112,"role":22,"phone":113,"phoneExt":11,"email":114},"Zhengyun Zou","13815891858","Zouzhengyun001@163.com",{"facility":116,"status":28,"city":117,"state":118,"zip":119,"country":32,"countryCode":33,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"The first affiliated hospital of Nanchang university","Nanchang","Jiangxi","330052",{"type":35,"coordinates":121},[122,123],115.85306,28.68396,{"lat":123,"lon":122},[126],{"name":127,"role":22,"phone":128,"phoneExt":11,"email":129},"Ling Zhang","13672215566","zhang_l202@163.com",{"facility":131,"status":28,"city":132,"state":133,"zip":134,"country":32,"countryCode":33,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Jilin Cancer Hospital","Changchun","Jilin","130012",{"type":35,"coordinates":136},[137,138],125.32278,43.88,{"lat":138,"lon":137},[141],{"name":142,"role":22,"phone":143,"phoneExt":11,"email":144},"Xueying Zhang","13304329877","554597526@qq.com",{"facility":146,"status":28,"city":132,"state":133,"zip":147,"country":32,"countryCode":33,"cosmosGeoPoint":148,"geoPoint":150,"contacts":151},"The first hospital of Jilin University","130021",{"type":35,"coordinates":149},[137,138],{"lat":138,"lon":137},[152],{"name":153,"role":22,"phone":154,"phoneExt":11,"email":155},"Di Wu","13944888991","wudi888991@163.com",{"facility":157,"status":28,"city":158,"state":159,"zip":160,"country":32,"countryCode":33,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Qilu Hospital of Shandong university","Jinan","Shandong","250012",{"type":35,"coordinates":162},[163,164],116.99722,36.66833,{"lat":164,"lon":163},[167],{"name":168,"role":22,"phone":169,"phoneExt":11,"email":170},"Cuihua Yi","18560082871","yicuihua@sdu.edu.cn",{"facility":172,"status":28,"city":173,"state":174,"zip":175,"country":32,"countryCode":33,"cosmosGeoPoint":176,"geoPoint":180,"contacts":181},"Shanxi Bethune Hospital","Taiyuan","Shanxi","030032",{"type":35,"coordinates":177},[178,179],112.56028,37.86944,{"lat":179,"lon":178},[182],{"name":183,"role":22,"phone":184,"phoneExt":11,"email":185},"Huijing Feng","15834121235","doctorfh@sina.com",{"facility":187,"status":28,"city":188,"state":189,"zip":190,"country":32,"countryCode":33,"cosmosGeoPoint":191,"geoPoint":195,"contacts":196},"Yunan Cancer Hospital","Kunming","Yunan","650118",{"type":35,"coordinates":192},[193,194],102.71833,25.03889,{"lat":194,"lon":193},[197],{"name":198,"role":22,"phone":199,"phoneExt":11,"email":200},"Ke Li","13888052830","likelikelike@162.com",{"type":202,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100522384","phase-2-a-study-of-ibi363-in-subjects-with-advanced-melanoma-100522384",false,"NCT06081920","A Study of IBI363 in Subjects With Advanced Melanoma","A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of IBI363 in Subjects With Advanced Melanoma","Inclusion Criteria:\n\n1. Histologically and\u002For cytologically confirmed, unresectable, locally advanced or metastatic melanoma (according to the American Joint Committee on Cancer (AJCC) 8th edition staging III-IV). Progression or recurrence after at least first-line systemic standard treatment.\n2. At least one measurable lesion (target lesion) per RECIST v1.1.\n3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.\n4. Life expectancy of 3 months or more.\n5. Female subjects of childbearing age or male subjects whose partners are female subjects of childbearing age agree to strictly adopt effective contraceptive measures throughout the entire treatment period and 6 months after the treatment period.\n\nExclusion Criteria:\n\n1. Pregnant or lactating subjects, or subjects who plan to conceive before, during, or within 6 months after the last dose of the study drug.\n2. Active or symptomatic central nervous system metastasis.\n3. At baseline (within 7 days before the first administration of the study drug), there were any hematological abnormalities as follows: hemoglobin\\\u003C90 g\u002FL; Absolute neutrophil count (ANC)\\\u003C1.5 × 109\u002FL; Platelet count\\\u003C100 × 109\u002FL.\n4. At baseline (within 7 days prior to first administration), there were any serum biochemical abnormalities as follows: Total bilirubin\\>1.5 × ULN; AST or ALT\\>3 × ULN; If it is tumor liver metastasis, AST or ALT\\>5.0 × ULN; Serum creatinine\\>1.5 × ULN or CCr\\\u003C45 mL\u002Fmin, using the Cockcroft Fault formula to calculate CCr (using actual body weight); Albumin\\\u003C30 g\u002FL.\n5. At baseline (within 7 days before first administration), there were any coagulation parameter abnormalities as follows: INR\\>1.5 × ULN (\\>3 if receiving anticoagulant therapy with stabilizer dosage) × ULN); PTT (or activated partial thromboplastin time (aPTT))\\>1.5 × ULN (\\>3 if receiving anticoagulant therapy with stabilizer dosage) × ULN).\n6. History of active thrombosis, deep vein thrombosis, or pulmonary embolism within 4 weeks prior to the first administration of the investigational drug, unless sufficient treatment has been given and the investigator believes that the condition is stable.\n7. Uncontrolled bleeding or known tendency to bleed.","ALL","18 Years",{"count":213,"type":214},180,"ESTIMATED","INTERVENTIONAL",[217],"PHASE2","This is an open-lable, multicenter Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients",[220],"Melanoma","2026-07-28",{"date":223,"type":224},"2026-07-29","ACTUAL",{"date":226,"type":224},"2023-10-19",{"date":228,"type":214},"2028-10-19",{"name":5,"class":6},12]